U.S. Markets closed

Venus Concept Announces First Quarter of Fiscal Year 2022 Financial Results; Reaffirms Fiscal Year 2022 Revenue Guidance

Venus Concept Inc.
Venus Concept Inc.

TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2022.

First Quarter 2022 Summary & Recent Highlights:

  • Total revenue of $26.4 million, up $3.8 million, or 17%, year-over-year.

    • U.S. revenue of $13.1 million, up $2.6 million, or 25%, year-over-year.

    • Total subscription and system revenue of $22.3 million, up $4.0 million, or 22% year-over-year.

  • GAAP net loss attributable to stockholders of $8.6 million, compared to a loss of $9.4 million last year.

  • Adjusted EBITDA loss of $5.9 million, compared to a loss of $5.0 million last year.

  • On January 18, 2022, the Company announced it had received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market the Venus BlissMAX device (“BlissMAX”) in the United States.

  • On March 31, 2022, the Company announced the submission of a 510(k) premarket notification to the FDA, which is intended to obtain a general clinical indication related to the use of its Aime™ next generation robotic technology for tissue excision and skin resurfacing.

  • On April 25, 2022, the Company announced that the first patient has been treated in a U.S. Investigational Device Exemption (“IDE”) clinical study evaluating the safety and efficacy of its Aime™ next generation robotic technology for the treatment of moderate to severe facial wrinkles.

  • On April 28, 2022, the Company announced it received a 510(k) clearance from the FDA to market Bliss MAX with an expanded indication for use in new areas of the body and an increase in RF energy output.

Management Commentary:

“First quarter revenue results were largely as expected, driven by more than 60% growth in sales of products in our ‘Body Franchise’ and 25% growth in sales to U.S. customers,” said Domenic Serafino, Chief Executive Officer of Venus Concept. “We continue to expect total revenue growth of 20% to 23% year-over-year in 2022 fueled by the commercial launch of BlissMAX, and we expect to drive continued improvements in our operating leverage, with the goal of generating positive cash flow in the fourth quarter of 2022. Our salesforce is executing our strategy to drive growth in sales of Bliss and BlissMAX in our ‘Body Franchise’ and sales of ARTAS iX and Neograft in our ‘Hair Restoration Franchise’. Our 2022 total revenue outlook continues to assume that more than 75% of our total revenue growth year-over-year comes from these two key growth franchises, which we expect will continue to fuel continued growth in sales of procedure-related recurring revenue and to be accretive to our total company gross margins. With multiple milestones achieved in recent months, we believe our clinical and regulatory strategies are progressing well particularly as it relates to AIME and BlissMAX. Our confidence in the long-term outlook for Venus Concept remains high.”

First Quarter 2022 Revenue by Region and by Product Type:

Three Months Ended March 31,

2022

2021

(dollars in thousands)

Revenues by region:

United States1

$

13,129

$

10,515

International

13,277

12,082

Total revenue

$

26,406

$

22,597


Three Months Ended March 31,

2022

2021

(dollars in thousands)

Revenues by product:

Subscription—Systems

$

10,423

$

8,537

Products—Systems

11,875

9,810

Products—Other (1)

3,497

3,055

Services (2)

611

1,195

Total revenue

$

26,406

$

22,597


(1)

Products-Other include ARTAS procedure kits and other consumables.

(2)

Services include extended warranty sales for the three months ended March 31, 2022. Services include extended warranty sales and VeroGrafters technician services for the three months ended March 31, 2021. VeroGrafters technician services were discontinued in the fourth quarter of 2021.


First Quarter 2022 Financial Results:

Three Months Ended March 31,

2022

2021

Change

(in thousands, except percentages)

$

% of Total

$

% of Total

$

%

Revenues:

Subscription—Systems

$

10,423

39.5

$

8,537

37.8

$

1,886

22.1

Products—Systems

11,875

45.0

9,810

43.4

2,065

21.0

Products—Other

3,497

13.2

3,055

13.5

442

14.5

Services

611

2.3

1,195

5.3

(584

)

(48.9

)

Total

$

26,406

100.0

$

22,597

100.0

$

3,809

16.9


Total revenue for the first quarter of 2022 increased $3.8 million, or 17%, to $26.4 million, compared to the first quarter of 2021. The increase in total revenue, by region, was driven by a 25% increase year-over-year in United States revenue and a 10% year-over-year increase in international revenue. The increase in total revenue, by product category, was driven by a 22% increase in lease revenue, a 21% increase in systems revenue and a 14% increase in products revenue, partially offset by a 49% decrease in services revenue. The percentage of total systems revenue derived from the Company’s subscription model was approximately 47% this quarter, consistent with the prior year period.

Gross profit for the first quarter of 2022 increased $2.5 million, or 17%, to $17.8 million compared to the first quarter of 2021. Gross margin was 67.3%, compared to 67.4% of revenue for the first quarter of 2021. The change in gross profit was primarily driven by an increase in revenue in the United States driven by the Company’s hair restoration business.

Operating expenses for the first quarter of 2022 were $25.2 million, compared to $22.1 million for the first quarter of 2021. The change in total operating expenses was driven by an increase of $2.0 million, or 26%, in sales and marketing expenses, an increase of $0.9 million, or 8%, in general and administrative expenses and an increase of $0.2 million, or 7%, in research and development expenses.

Operating loss for the first quarter of 2022 was $7.4 million, compared to $6.8 million for the first quarter of 2021.

Net loss attributable to stockholders for the first quarter of 2022 decreased $0.6 million, or 7% year-over-year, to $8.6 million, or $0.13 per share. Adjusted EBITDA loss for the first quarter of 2022 increased $0.9 million, or 17% year-over-year, to $5.9 million.

Fiscal Year 2022 Revenue Guidance:

The Company continues to expect total revenue for the twelve months ending December 31, 2022 in the range of $126 million to $130 million, representing an increase of approximately 20% to 23%, year-over-year, compared to total revenue of $105.6 million for the twelve months ended December 31, 2021.

Conference Call Details:

Management will host a conference call at 5:00 p.m. Eastern Time on May 12, 2022 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13728704. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13728704. The webcast will be archived at ir.venusconcept.com.

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 18 direct markets. Venus Concept focuses its product sales strategy on a subscription-based business model in North America and in its well-established direct global markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve and Venus Viva MD. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS® and ARTAS iX® Robotic Hair Restoration systems. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, statements about our financial performance; the growth in demand for our systems and other products; and general economic conditions, including the global economic impact of COVID-19, and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part II Item 1A—“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.


Venus Concept Inc.
Condensed Consolidated Balance Sheets
(Unaudited)

(In thousands of U.S. dollars, except share and per share data)

March 31,

December 31,

2022

2021

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

$

17,911

$

30,876

Accounts receivable, net of allowance of $12,742 and $11,997 as of March 31, 2022, and December 31, 2021

49,076

46,918

Inventories

21,319

20,543

Prepaid expenses

2,446

2,737

Advances to suppliers

3,532

2,162

Other current assets

4,139

3,758

Total current assets

98,423

106,994

LONG-TERM ASSETS:

Long-term receivables

27,747

27,710

Deferred tax assets

249

284

Severance pay funds

884

817

Property and equipment, net

2,583

2,669

Intangible assets

14,536

15,393

Total long-term assets

45,999

46,873

TOTAL ASSETS

$

144,422

$

153,867

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:

Trade payables

$

4,788

$

4,913

Accrued expenses and other current liabilities

18,818

19,512

Income taxes payable

415

294

Unearned interest income

2,727

2,678

Warranty accrual

1,127

1,245

Deferred revenues

1,585

2,030

Current portion of government assistance loans

136

543

Total current liabilities

29,596

31,215

LONG-TERM LIABILITIES:

Long-term debt

77,404

77,325

Income tax payable

571

563

Accrued severance pay

994

911

Deferred tax liabilities

56

46

Unearned interest income

1,376

1,355

Warranty accrual

432

508

Other long-term liabilities

567

348

Total long-term liabilities

81,400

81,056

TOTAL LIABILITIES

110,996

112,271

Commitments and Contingencies (Note 8)

STOCKHOLDERS’ EQUITY:

Common Stock, $0.0001 par value: 300,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 63,999,044 and 63,982,580 issued and outstanding as of March 31, 2022 and December 31, 2021 respectively

27

27

Additional paid-in capital

221,787

221,321

Accumulated deficit

(189,024

)

(180,405

)

TOTAL STOCKHOLDERS’ EQUITY

32,790

40,943

Non-controlling interests

636

653

33,426

41,596

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

144,422

$

153,867


Venus Concept Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands of U.S. dollars, except per share data)

Three Months Ended March 31,

2022

2021

Revenue

Leases

$

10,423

$

8,537

Products and services

15,983

14,060

26,406

22,597

Cost of goods sold

Leases

2,700

1,770

Products and services

5,943

5,593

8,643

7,363

Gross profit

17,763

15,234

Operating expenses:

Sales and marketing

9,903

7,854

General and administrative

13,094

12,165

Research and development

2,202

2,051

Total operating expenses

25,199

22,070

Loss from operations

(7,436

)

(6,836

)

Other expenses:

Foreign exchange loss

5

714

Finance expenses

923

1,885

Loss before income taxes

(8,364

)

(9,435

)

Income tax expense

272

-

Net loss

(8,636

)

(9,435

)

Net loss attributable to stockholders of the Company

(8,619

)

(9,259

)

Net loss attributable to non-controlling interest

(17

)

(176

)

Net loss per share:

Basic

$

(0.13

)

$

(0.17

)

Diluted

$

(0.13

)

$

(0.17

)

Weighted-average number of shares used in per share calculation:

Basic

63,988

53,744

Diluted

63,988

53,744


Use of Non-GAAP Financial Measures

Adjusted EBITDA is a non-GAAP measure defined as net income (loss) before foreign exchange loss (gain), financial expenses, income tax expense (benefit), depreciation and amortization, stock-based compensation and non-recurring items for a given period. Adjusted EBITDA is not a measure of our financial performance under U.S. GAAP and should not be considered an alternative to net income or any other performance measures derived in accordance with U.S. GAAP. Accordingly, you should consider Adjusted EBITDA along with other financial performance measures, including net income, and our financial results presented in accordance with U.S. GAAP. Other companies, including companies in our industry, may calculate Adjusted EBITDA differently or not at all, which reduces its usefulness as a comparative measure. We understand that although Adjusted EBITDA is frequently used by securities analysts, lenders and others in their evaluation of companies, Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are: Adjusted EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments; Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; and although depreciation and amortization are non-cash charges, the assets being depreciated will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.

We believe that Adjusted EBITDA is a useful measure for analyzing the performance of our core business because it facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by changes in foreign exchange rates that impact financial assets and liabilities denominated in currencies other than the U.S. dollar, tax positions (such as the impact on periods or companies of changes in effective tax rates), the age and book depreciation of fixed assets (affecting relative depreciation expense), amortization of intangible assets, stock-based compensation expense (because it is a non-cash expense) and non-recurring items as explained below.

The following reconciliation of net loss to Adjusted EBITDA for the periods presented:


Venus Concept Inc.
Reconciliation of Net loss to Non-GAAP Adjusted EBITDA

Three Months Ended March 31,

2022

2021

Reconciliation of net loss to adjusted EBITDA

(in thousands)

Net loss

$

(8,636

)

$

(9,435

)

Foreign exchange loss

5

714

Finance expenses

923

1,885

Income tax expense

272

Depreciation and amortization

1,101

1,304

Stock-based compensation expense

443

508

Adjusted EBITDA

$

(5,892

)

$

(5,024

)


1 Revenue by region for the three months ended March 31, 2021 reflect reclassification of $362 from United States to International; see note 2 in the Company’s form 10-Q for the three months ended March 31, 2022.

CONTACT: Investor Relations Contact: ICR Westwicke on behalf of Venus Concept: Mike Piccinino, CFA VenusConceptIR@westwicke.com